FDA Endorses Teplizumab

Previously Published on Medscape.com – A US Food and Drug Administration (FDA) advisory panel has voted narrowly to recommend approval of the monoclonal antibody teplizumab (Tzield,Provention Bio) for the delay of type 1 diabetes in at-risk individuals. (FDA Endorses Teplizumab) The 10-7 vote of the FDA’s Endocrinologic and Metabolic Drugs advisory committee on May 27 reflected a…